Regulatory milestones for sovleplenib are accelerating with two NDA acceptances in China within months. Watch for EHA 2026 presentation of Phase III wAIHA data and NMPA decision timeline, which could drive near-term catalysts. The ITP NDA resubmission with priority review is also a key parallel catalyst.
Price Chart
Executive Summary
HUTCHMED announced that its NDA for sovleplenib in warm antibody autoimmune hemolytic anemia (wAIHA) was accepted for review by the NMPA with Priority Review and Breakthrough Therapy Designation. This is the second NDA for sovleplenib, following its ITP filing, and expands the drug's potential in a rare autoimmune disease with limited treatment options. The Phase III ESLIM-02 trial met its primary endpoint in January 2026, with full results pending at EHA 2026.
Key Facts
- NDA for sovleplenib in wAIHA accepted for review by China NMPA with Priority Review status
- Breakthrough Therapy Designation granted by NMPA in March 2026
- Second NDA for sovleplenib; first NDA (for ITP) resubmitted and granted priority review in February 2026
- Phase III ESLIM-02 trial met primary endpoint of durable hemoglobin response rate in January 2026
- Phase II results showed 43.8% overall response rate vs 0% placebo at 8 weeks, and 66.7% over 24 weeks
- HUTCHMED retains all worldwide rights to sovleplenib
- wAIHA accounts for ~75-80% of adult AIHA cases; estimated prevalence of 17 per 100,000 adults
Financial Impact
No financial figures provided in filing. Potential future revenue from wAIHA indication if approved, but no market size or revenue estimates disclosed.
Risk Factors
- Regulatory approval is not guaranteed; NMPA may request additional data or deny the NDA
- Competition from existing and emerging wAIHA therapies could limit market share
- Commercial execution in China depends on pricing, reimbursement, and physician adoption
- Sovleplenib is still investigational; safety and efficacy in larger populations are not fully established
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000026 |
| Document: hcm-20260429x6k.htm | 0001648257-26-000026 |
| Document: 0001648257-26-000026-index-headers.html | 0001648257-26-000026 |
| Document: 0001648257-26-000026-index.html | 0001648257-26-000026 |
| Document: 0001648257-26-000026.txt | 0001648257-26-000026 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 21, 2026 22w ago | 6-K | $2.16 $2.16 | · 0.00% | ▼ −4.30% | $2.16 (+0.00%) |
May 12, 2026 23w ago | 6-K | $2.82 $2.16 | ▼ −23.40% | ▼ −27.79% | $2.16 (−23.40%) |
Apr 29, 2026 25w ago | 6-K | $2.82 $2.16 | ▼ −23.40% | ▼ −27.52% | $2.16 (−23.40%) |
Apr 9, 2026 28w ago | 6-K | $2.82 $2.90 | ▲ +2.84% | ▼ −7.94% | $2.16 (−23.40%) |
Apr 9, 2026 28w ago | 6-K | $2.82 $2.90 | ▲ +2.84% | ▼ −7.94% | $2.16 (−23.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers